Printer Friendly

FDA ADVISORY COMMITTEE TO REVIEW CANCER IMAGING PRODUCT

 FDA ADVISORY COMMITTEE TO REVIEW CANCER IMAGING PRODUCT
 PRINCETON, N.J., Dec. 20 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today that the FDA's Biological Response Modifiers Advisory Committee has announced that it will be reviewing the Product License Application (PLA) for OncoScint OV103, a monoclonal antibody-based diagnostic imaging agent, at a meeting set for 10 a.m. on Jan. 16, 1992.
 Notice of this meeting is published in the Federal Register dated Dec. 20, 1991. The PLA for OncoScint OV103 was filed in March of 1990 and had been previously designated by the FDA as an Orphan Drug.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies. The company is developing a broad range of monoclonal antibody-based cancer imaging agents.
 /delval/
 -0- 12/20/91
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU:


MP -- PH002 -- 4232 12/20/91 09:02 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:162
Previous Article:BRAJDAS CORP. ENTERS INTO MERGER AGREEMENT
Next Article:CORDIS HYDROCEPHALUS VALVE GAINS MARKET APPROVAL
Topics:


Related Articles
FDA ADVISORY COMMITTEE ENDORSES CYTOGEN PRODUCT AS FIRST MAB-BASED CANCER IMAGING AGENT IN THE UNITED STATES
NEORX RECEIVES FAVORABLE FDA REVIEW LETTER
FDA PANEL SCHEDULED TO REVIEW LEUKINE APPLICATION FOR NEW USE
IMMUNOMEDICS' CEA-SCAN UNANIMOUSLY RECOMMENDED FOR U.S. APPROVAL BY FDA PANEL
GLIADEL WAFER TO BE REVIEWED BY FDA ADVISORY COMMITTEE
FDA Panel Recommends Approval of Thyrogen
FDA Panel Votes to Recommend Approval of GE Digital Mammography System.
FDA Advisory Committee Recommends Approval of Mentor's Premarket Approval (PMA) Application for Saline-Filled Breast Implants.
FDA Advisory Committee Recommends Approval of Mentor's Premarket Approval (PMA) Application for Saline-Filled Breast Implants.
Computerized Thermal Imaging Establishes Medical Advisory Board for Breast Imaging System.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters